Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia
暂无分享,去创建一个
S. Rosenberg | M. Sabatino | M. Stetler-Stevenson | D. Stroncek | T. Fry | C. Mackall | J. Kochenderfer | Yongzhi Cui | C. Yuan | B. Yates | Daniel W. Lee | N. Shah | Ling Zhang | A. Wayne | Nicholas P. Tschernia | Hua Zhang | Steven R. Feldman | Cindy P. Delbrook